Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):423-426. doi: 10.1007/s10096-018-3429-x. Epub 2018 Nov 15.

Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

Keywords: Abacavir/lamivudine; Efficacy; Raltegravir; Rilpivirine; Safety; Switching.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / economics
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Antiretroviral Therapy, Highly Active / economics
  • Dideoxynucleosides / adverse effects
  • Dideoxynucleosides / pharmacology
  • Dideoxynucleosides / therapeutic use
  • Drug Combinations
  • Drug Resistance, Viral / genetics
  • Drug Substitution
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Lamivudine / adverse effects
  • Lamivudine / pharmacology
  • Lamivudine / therapeutic use
  • Raltegravir Potassium / adverse effects
  • Raltegravir Potassium / therapeutic use
  • Rilpivirine / adverse effects
  • Rilpivirine / therapeutic use
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • Drug Combinations
  • abacavir, lamivudine drug combination
  • Lamivudine
  • Raltegravir Potassium
  • Rilpivirine